Spero Therapeutics - SPRO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.00
  • Forecasted Upside: 410.95%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.37
▲ +0.04 (3.01%)

This chart shows the closing price for SPRO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Spero Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SPRO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SPRO

Analyst Price Target is $7.00
▲ +410.95% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Spero Therapeutics in the last 3 months. The average price target is $7.00, with a high forecast of $7.00 and a low forecast of $7.00. The average price target represents a 410.95% upside from the last price of $1.37.

This chart shows the closing price for SPRO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Spero Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/31/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00Low
4/4/2024Cantor FitzgeraldReiterated RatingOverweightLow
3/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00Low
12/18/2023Cantor FitzgeraldReiterated RatingOverweightLow
11/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$7.00Low
9/5/2023HC WainwrightReiterated RatingBuy ➝ Buy$7.00Low
8/14/2023HC WainwrightBoost TargetBuy ➝ Buy$6.00 ➝ $7.00Low
8/1/2023HC WainwrightReiterated RatingBuy ➝ Buy$6.00Low
4/10/2023HC WainwrightReiterated RatingBuy$6.00Low
3/31/2023Cantor FitzgeraldReiterated RatingOverweightLow
9/26/2022HC WainwrightLower TargetBuy$7.00 ➝ $6.00Low
9/22/2022Evercore ISIUpgradeIn-Line ➝ Outperform$8.00Low
8/15/2022HC WainwrightLower TargetBuy$10.00 ➝ $7.00Low
5/23/2022HC WainwrightLower TargetBuy$37.00 ➝ $10.00Medium
5/20/2022Berenberg BankDowngradeBuy ➝ HoldHigh
5/17/2022Cantor FitzgeraldLower Target$27.00 ➝ $5.00High
5/4/2022CowenDowngradeOutperform ➝ Market PerformMedium
4/18/2022HC WainwrightLower TargetBuy$43.00 ➝ $37.00High
3/21/2022HC WainwrightBoost TargetBuy$40.00 ➝ $43.00High
10/1/2021OppenheimerDowngradeOutperform ➝ Market PerformHigh
8/8/2021Evercore ISIReiterated RatingBuy$70.00Low
6/1/2021HC WainwrightReiterated RatingBuy$40.00Medium
1/22/2021HC WainwrightBoost TargetBuy$33.00 ➝ $40.00High
12/16/2020Berenberg BankInitiated CoverageBuy$47.00High
11/23/2020HC WainwrightBoost TargetBuy$28.00 ➝ $33.00High
10/25/2020OppenheimerReiterated RatingBuy$19.00High
9/29/2020Evercore ISIInitiated CoverageOutperformHigh
9/8/2020OppenheimerReiterated RatingBuy$20.00High
9/8/2020Stifel NicolausReiterated RatingBuy$21.00 ➝ $25.00High
8/31/2020OppenheimerReiterated RatingBuyHigh
6/2/2020HC WainwrightReiterated RatingBuy$28.00High
5/11/2020HC WainwrightBoost TargetBuy$25.00 ➝ $28.00High
5/8/2020OppenheimerInitiated CoverageBuy$20.00High
3/17/2020Cantor FitzgeraldReiterated RatingOverweightLow
3/17/2020Stifel NicolausLower TargetBuy$22.00 ➝ $21.00High
1/21/2020HC WainwrightReiterated RatingBuy$35.00Low
12/11/2019HC WainwrightReiterated RatingBuy$35.00Low
11/5/2019CowenReiterated RatingBuyMedium
11/5/2019HC WainwrightBoost TargetBuy$28.00 ➝ $35.00Medium
10/2/2019OppenheimerLower Target$30.00 ➝ $20.00Low
9/9/2019Janney Montgomery ScottInitiated CoverageBuyHigh
9/4/2019HC WainwrightReiterated RatingBuy$28.00Medium
8/12/2019HC WainwrightReiterated RatingBuy$27.00Low
(Data available from 6/24/2019 forward)

News Sentiment Rating

0.66 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2024
  • 6 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2024
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/25/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2024

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Spero Therapeutics logo
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $1.37
Low: $1.33
High: $1.38

50 Day Range

MA: $1.48
Low: $1.27
High: $1.69

52 Week Range

Now: $1.37
Low: $0.99
High: $1.89

Volume

115,100 shs

Average Volume

254,555 shs

Market Capitalization

$73.97 million

P/E Ratio

3.19

Dividend Yield

N/A

Beta

0.64

Frequently Asked Questions

What sell-side analysts currently cover shares of Spero Therapeutics?

The following equities research analysts have issued reports on Spero Therapeutics in the last year: Cantor Fitzgerald, and HC Wainwright.
View the latest analyst ratings for SPRO.

What is the current price target for Spero Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Spero Therapeutics in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 410.9%. HC Wainwright has the highest price target set, predicting SPRO will reach $7.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $7.00 for Spero Therapeutics in the next year.
View the latest price targets for SPRO.

What is the current consensus analyst rating for Spero Therapeutics?

Spero Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SPRO will outperform the market and that investors should add to their positions of Spero Therapeutics.
View the latest ratings for SPRO.

What other companies compete with Spero Therapeutics?

How do I contact Spero Therapeutics' investor relations team?

Spero Therapeutics' physical mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company's listed phone number is (857) 242-1600 and its investor relations email address is [email protected]. The official website for Spero Therapeutics is sperotherapeutics.com. Learn More about contacing Spero Therapeutics investor relations.